(Total Views: 78)
Posted On: 09/22/2022 11:10:48 AM
Post# of 36281

$MRK News Article - LYNPARZA (olaparib) Approved in China as First-Line Maintenance Treatment With Bevacizumab for Homologous Recombination Deficient (HRD)-Positive Advanced Ovarian Cancer https://marketwirenews.com/news-releases/lynp...96823.html


My Twitter: WhyteStocks